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Summary
Although relatively effective diagnostic tests for brucellosis have been in 
existence for more than 100 years, it remains a serious, embedded and also a 
re-emerging disease in many parts of the globe. There are many factors besides 
suboptimal diagnosis that impede the complete and sustained eradication of 
animal brucellosis. In this review a case for the continued improvement of 
diagnostic methods is made through identifying existing shortcomings and 
considering what impact these have upon control and eradication. The focus is 
on developments in immunodiagnostics as these seem more likely to yield the 
pragmatic solutions needed. Moreover, developments in DNA detection methods 
have been neatly and recently reviewed elsewhere. This article reviews issues 
such as test cost, mobility, sensitivity and specifi city. Advances in low-cost 
materials, high-throughput testing, assay multiplexing and the quantifi cation of 
pen-side tests are described and their relevance to disease control considered. 
Poor test specifi city when resolving positive serology, due to infection with 
cross-reactive bacteria and vaccination with smooth Brucella strains, is also 
an impediment to effi cient disease eradication. A case for the development of 
novel discrete epitope antigens to address this is presented alongside in silico 
methods of selection and tools that enable increased analytical sensitivity that 
may be required to detect relatively low, but potentially signifi cant, analytes. 
References have been drawn from the study of brucellosis wherever possible. 
However, in some cases new technological developments worthy of discussion 
have been included via the use of pertinent alternative examples. In conclusion, 
despite developments and innovations the classical serological tests seem 
under no imminent danger of mass extinction but there is potential for signifi cant 
improvement and supplementation. 
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Introduction
Brucellosis is a global disease, endemic in many areas, and 
present in most countries. Even in regions that are free of the 
disease the threat of reintroduction into livestock or wildlife 
means that considerable costs continue to be incurred. 
The diagnosis of brucellosis in animals is complicated by 
the paucity of reliable clinical signs. This makes clinical 
diagnosis unreliable unless there is strong supporting 
epidemiological information; however, this is frequently 
absent. Bacterial culture plays an important part in 
confi rming the presence of disease but, other than samples 
collected from an abortion event, the likelihood of obtaining 
a positive culture from material from a live infected animal 
is too low for reliable diagnosis. Furthermore, culture is not 
an appropriate technique for routine screening owing to the 
costs, diffi culties and dangers that it presents. Alternative 
diagnostic approaches include DNA amplifi cation and 
detection methods, but the effectiveness of such approaches 
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on readily available material such as blood, serum, swabs 
and milk has yet to be fully evaluated and existing 
information is confl icting (81).
Serology is the mainstay of diagnosis for brucellosis because 
the diagnostic material is relatively easily accessible, and the 
tests are relatively cheap, available and sensitive. Alongside 
many other crucial components (7), the currently available 
serodiagnostic assays have been shown to be capable of 
enabling the sustained eradication of brucellosis. However, 
the cost of the ongoing commitment to serology and 
infrastructural support is prohibitive and few countries 
have totally eradicated the disease – in many the situation is 
getting worse (69). What, if any, innovations in serodiagnosis 
would reduce the burden on the complementary resources 
that are needed for effective disease surveillance, control 
and eradication? What are the signifi cant imperfections in 
immunodiagnosis to be addressed?
There are four main areas where improvements in 
serodiagnosis may signifi cantly assist in the control and 
sustained eradication of brucellosis: 
– reducing the cost
– increasing the specifi city
– improving mobility
– developing a reliable assay that can differentiate infected 
from vaccinated animals (DIVA assay). 
The relative importance of each of these will vary according 
to the situation to which the assays are to be applied. For 
example, in areas of moderate to low prevalence the ability 
to run consecutive vaccination and test and slaughter 
campaigns could reduce the time and effort required to 
eliminate the disease. Whether this is already possible is an 
area of some debate (52). In areas with limited veterinary 
infrastructure and unmonitored animal movements a 
reliable fi eld assay may be of value. In regions where 
the disease has been eradicated but ongoing serological 
surveillance is required the positive predictive value of the 
assays is very low. Increasing specifi city would reduce the 
need for costly and frequently unnecessary interventions. 
Effective surveillance for brucellosis often requires high-
throughput testing, and any developments that would lead 
to a reduction in the cost of a serological result would leave 
more resources available elsewhere. Many of the routinely 
used serodiagnostic assays already have a high diagnostic 
sensitivity (25), yet methods leading to improvements in 
analytical sensitivity may yield improvements in specifi city, 
as described later. 
The Rose Bengal test (RBT) (56) in many respects sets a 
tough benchmark to improve upon. It is simple to perform, 
rapid, homogeneous, sensitive, the sample (serum) is 
accessible, the consumables are cheap, there is a low 
equipment requirement and the assay is standardised (59). 
It is a respectable assay (22). However, it is labour intensive, 
usually interpreted in a subjective manner (but not always), 
there is no multiplex capability, it is prone to false positive 
serological reactions (FPSRs), false negative results may 
occur due to prozoning (58) and it has limited mobility 
because it does not work with whole blood or plasma. 
Reducing test cost
The most obvious way to reduce test costs is to reduce 
the cost of the test reagents and the cost of the equipment 
required. The RBT already sets a high standard here with its 
simplicity and relatively low cost. It may be that innovations 
in paper-based microfl uidics will lead to a generation of 
tests that are equally simple to run and whose reagents and 
consumables are more affordable and easily stored (41, 
51). Samples themselves, such as serum, can be stored on 
paper and the antibodies released for subsequent diagnostic 
analysis, as demonstrated for brucellosis (16). This may 
reduce the costs and risks associated with the distribution 
(to a confi rmatory testing laboratory, for example) and 
storage of such samples.
Test costs may also be reduced when serological testing 
requirements are large, as they often are, by developing 
ever more effi cient high-throughput methods. Where 
labour costs are high compared to reagent and equipment 
costs, systems that enable automation of assay performance, 
output and sample reporting provide long-term cost saving 
opportunities. Minimising the number of intervention 
steps in the diagnostic assay reduces ‘hands on’ time and 
automation requirements. Automation can be performed 
with basic assays such as the RBT (11, 28), but automation 
is much more readily available for assays in 96-well format, 
such as enzyme-linked immunosorbent assay (ELISA). 
Combining the automation with integrated sample tracking 
via a laboratory information management system can offer 
even greater effi ciency savings (46). The effi ciencies of 
ELISA, such as the application of a standard 96-well format 
and quantitative output, are also utilised by the fl uorescent 
polarisation assay (FPA) and the time-resolved fl uorescent 
resonance energy transfer (TR-FRET) formats, which have 
both been evaluated for brucellosis serology. These claim 
to offer similar diagnostic performance to ELISA (49, 60), 
the former being prescribed by the World Organisation 
for Animal Health (OIE) for international trade, and they 
are rapid, quantitative and homogeneous, such that the 
antigen–antibody reaction takes place in the liquid phase 
and is detected via fl uorescent labels without subsequent 
washing or separation steps. The TR-FRET can also be used 
in a duplex format for the simultaneous detection of two 
analytes, e.g. antibodies to human immunodefi ciency virus 
and hepatitis B surface antigen in human sera (57). 
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This minimalist interventional approach is also the theme 
of several other technologies that have been adapted for 
serodiagnostic purposes. Some of these, such as dynamic 
light scattering (DLS) and surface plasmon resonance (SPR), 
offer ‘label-free’ detection, although for immunodetection 
some element of bimolecular conjugation is required at 
some stage in the process. The DLS method is frequently 
used to measure nanoparticle size, such as during antibiotic 
delivery (70) and vaccine production (17), and it can 
also be used to measure the formation of polymers (3). 
The highly effi cient light-scattering properties of gold 
nanoparticles, which may be conjugated with antigens or 
antibodies, enable these to be employed to create sensitive 
immunoassays where aggregation is measured by DLS. This 
has been demonstrated in the detection of infl uenza virus 
using antibody-coated gold nanoparticles (19). The DLS 
method is a one-step homogeneous quantitative method 
which, in the case of infl uenza virus detection, also offers 
an increase in analytical sensitivity of 1 to 2 orders of 
magnitude compared with commercially available kits. 
Surface plasmon resonance has been offered as a detection 
platform from Biacore for several years and many studies 
relating to antigen–antibody binding have been performed 
and published, including for the detection of porcine 
serum antibodies to Salmonella lipopolysaccharide (LPS) 
(2). Surface plasmon resonance is essentially a means of 
measuring small changes in refractive index that occur 
in response to analyte binding at, or near, the metal fi lm 
surface. Real-time antibody binding kinetics can be 
evaluated using this system and conjugated surfaces can 
be reused. However, the Biacore hardware is expensive and 
the throughput is limited by the number of fl ow cells, a 
maximum of eight per reader, although a sample read cycle 
is claimed to be as short as four minutes. A localised (L)
SPR system that uses colloidal metal nanoparticles and 
is potentially more suited to high-throughput screening 
has more recently been developed (31). Based on this 
principle, PharmaDiagnostics NV has developed carboxyl-
functionalised gold nanorods, which are now available as 
SoPRanoTM technology to detect biomolecular interactions. 
The assay requires no separation steps, can be performed 
in 96- and 384-well formats, and data (Fig. 1) are collected 
via an absorbance plate reader capable of reading in the 
low to near infrared region, such as the POLARstar Omega 
from BMG Labtech. Preliminary work (Dr Vanessa Bonnard, 
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Fig. 1
Absorption spectrum from a localised surface plasmon 
resonance assay for the detection of anti-Brucella monoclonal 
antibody
A graph of optical density (OD) against wavelength (nm) for localised 
surface plasmon resonance of gold nanorods conjugated with 
Brucella O-polysaccharide (OPS) incubated with buffer only (Blank), anti-
Brucella OPS monoclonal antibody at 200 nM concentration in buffer 
(anti-OPS mAb) and anti-human serum albumin monoclonal antibody 
(anti-hSA mAb) at 200 nM concentration. The embedded graph shows 
the OD at λmax with greater resolution and demonstrates the red shift 
in λmax that has occurred as a consequence of incubation with the anti-
Brucella OPS mAb
Source: Data courtesy of Vanessa Bonnard from PharmaDiagnostics NV
Fig. 2
Detection of anti-Brucella O-polysaccharide monoclonal 
antibody by localised surface plasmon resonance assay
This graph shows changes in RU (obtained from a ratiometric analysis 
defi ned as the OD at λmax[blank] + 80 nm / OD at λmax) of Brucella 
OPS conjugated gold nanorods (-axis) against the concentration of 
co-incubated anti-Brucella OPS monoclonal antibody (mAb; x-axis) 
for four different nanorod preparations (conjugated with 150, 38, 15 
or 0 µg/ml of Brucella OPS, all capped with polyethylene glycol [PEG]). 
The embedded graph shows the same data with greater resolution in the 
range of 0 to 15 nM of mAb
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nanorods conjugated to the O-polysaccharide (OPS) from 
B. melitensis has demonstrated that the system is capable 
of specifi cally detecting an anti-Brucella OPS monoclonal 
antibody within the nM concentration range (Fig. 2). This 
puts the analytical sensitivity in the realm of that required 
for a serodiagnostic assay (49).
Other particle-based detection platforms can also be 
adapted to separation-free serodiagnosis. These include the 
AlphaLISATM (Perkin Elmer) system, based on luminescent 
oxygen channelling (74), which has been shown to be 
effective for the detection of anti-Brucella antibodies in 
ruminant serum (47). An alternative separation-free system 
is the 96-well format system from MesoScaleDiscovery 
(MSD). This applies electrochemiluminescence (ECL) 
to derive a proximity-based antibody-dependent signal 
and has been successfully used for the detection of anti-
Brucella smooth lipopolysaccharide (sLPS) antibodies in 
serum (72). The ECL excitation energy is provided via the 
plate surface, where the antibody–antigen interaction takes 
place in much the same manner as in an ELISA. This means 
that the system can also be used, like ELISA, with a more 
‘traditional’ separation-based protocol. This may in theory 
increase the analytical sensitivity and dynamic range of the 
assay – but not always (72). 
Multiplexing
An alternative strategy to reduce the expense of gathering 
serological data is to share the costs by creating multiplex 
assays that detect antibodies to antigens from several 
different pathogens simultaneously within the same reaction 
vessel. Such assays may be in suspension ‘fl ow-cytometer’ 
or planar formats (37). The previously mentioned MSD 
platform can be used for multiplex testing in planar form 
(as well as the separation-free application described above). 
This capability has been demonstrated by the simultaneous 
detection of bovine serum antibodies against four antigens 
for different respiratory diseases (53). A bovine cytokine 
multiplex has also been developed for this platform (13) 
and applied to the study of bovine tuberculosis. In theory, 
it should be possible to perform separation-free multiplex 
assays on this platform, and the manufacturers state 
that such assays have been developed by some of their 
pharmaceutical clients but not published. 
A programme to monitor a range of infectious diseases in 
European wildlife (www.wildtechproject.com/wildtech/) 
is taking a multiplex approach to serodiagnosis in 
order to develop and apply effi cient means to estimate 
seroprevalence. One of the platforms selected is Luminex®. 
This is a suspension array 96-well format which uses 
different populations of beads that can each be specifi cally 
conjugated and fl uorescently identifi ed. As part of the 
antigen selection process several Brucella antigens have 
been conjugated to specifi c bead populations, including 
B. suis 1330 (whole cell), B. abortus rough LPS, recombinant 
BP26 (48), as well as a Yersinia enterocolitica O:9 (whole cell) 
antigen. Preliminary data from this study are encouraging, 
and supportive of the multiplex approach (Drs Liljana 
Petrovska and Antonia Touloudi, personal communication). 
The application of the Luminex® platform to the detection 
of antibodies against some viral antigens of veterinary 
signifi cance has already been published (5).
The ‘Wildtech’ project is also developing a planar serological 
array using the ArrayStripTM (CLONDIAG) platform (21), 
where up to 441 different antigens in a 21 × 21 array may 
be printed in discrete locations within a test well. This is 
a highly proprietary platform with a relatively constrained 
business model. A more open approach is to print antigens 
in a discrete array directly into wells of standard plastic 
96-well ELISA plates, and to capture antibody-dependent 
chemiluminescence using a digital camera. Printing can be 
done, for example, using a nanolitre printer such as those 
available from BioDot and results recorded using a digital 
imaging system such as that from Quansys Biosciences. 
This system has been used to create the ‘Enferplex’ assay for 
the detection of antibodies to multiple antigen targets from 
Mycobacterium bovis (71, 82). In this case the strategy has 
been to measure the antibody response simultaneously to 
a range of antigens from the same pathogen. The objective 
is to increase the sensitivity and specifi city of the overall 
diagnostic output, via the use of an algorithm incorporating 
the response to each antigen, in a manner that is cost 
effective and therefore practicable.
Simultaneous immunoassay multiplexes have also been 
developed through the application of surface enhanced 
Raman scattering (SERS) technology. A ‘proof of concept’ 
study simultaneously and differentially detected human, 
mouse, rat and rabbit immunoglobulin (Ig)G (77). 
Multiplexing of SERS assays is possible owing to the 
tuneable fl uorescent wavelengths and narrow fl uorescent 
bandwidths of the nanoparticles used. Developments in 
this technology are rapidly emerging, and the advent of a 
dual SERS–fl uorescence coding approach seems to offer 
the potential to massively increase the number of analytes 
differentially detected in one go (79). Yet this is not the 
most exciting aspect of this technology – it is the exquisite 
analytical sensitivity that delivers the radical opportunities. 
Increasing analytical sensitivity
The application of colloidal metal nanoparticles to 
Raman Scattering to develop SERS has enhanced the 
sensitivity of this approach by many orders of magnitude, 
up to a staggering 1,014 times, to the point where the 
method is capable of detecting a single antigen–antibody 
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interaction (63). This approach has been applied to the 
antibody-mediated detection of Mycobacterium avium 
subsp. paratuberculosis with reported detection limits 
in milk of less than 1,000 colony-forming units (cfu)/ml 
(83). In conjunction with immunomagnetic separation, a 
SERS immunoassay for Escherichia coli reported a limit of 
detection of 8 cfu/ml (30). Thus, immunoassays, including 
those with multiplexing capability, have moved into the 
realms of analytical sensitivity only previously available 
through DNA detection. 
Increasing analytical sensitivity does not directly correlate 
with increases in diagnostic sensitivity or specifi city. In many 
cases increased sensitivity leads to a decrease in specifi city. 
Why should those with an interest in the diagnosis of 
brucellosis be interested in this? Some antibodies, such as 
those raised against the Brucella OPS, are preponderant, and 
existing immunoassays such as the sLPS indirect (i)ELISA 
already have good diagnostic sensitivity. Increasing the 
analytical sensitivity of such assays may lead to reductions 
in specifi city, as antibodies generated against similar 
structures from other Gram-negative bacteria may generate 
FPSRs (15). Other antigens of interest to the diagnostician 
may elicit a lower level of antibody response, and increasing 
the capability to detect these may be of value. Increasing 
sensitivity to enable the detection of antibodies against less 
immunodominant, but more specifi c, antigens may yield 
assays with improved specifi city. 
Although SERS techniques currently seem to represent the 
gold standard in immunoassay sensitivity, the platform is 
beyond the means of most diagnostic laboratories and the 
same might be said of metal nanoparticle DLS. Alternative 
means of increasing analytical sensitivity are more 
accessible. Immuno-polymerase chain reaction (PCR) is an 
interesting technique for antigen and antibody detection 
that has recently been reviewed (50), and a homogeneous 
analogue would be the proximity ligation assay (29), 
reagents for which are available from OlinkTM. Time-
resolved fl uorescence (TRF) using long lifetime lanthanide 
fl uorophore biomarkers is also reported to increase 
assay sensitivity over standard fl uorescence techniques. 
The incorporation of these fl uorophores in conjugative 
microspheres further increases the sensitivity by multiplying 
the number of fl uorophores that signal each binding event. 
These microspheres also increase the analytical sensitivity 
of homogeneous TR-FRET reactions (75). The use of 
streptavidin poly-HRP (horseradish peroxidase) is probably 
the easiest means of increasing assay sensitivity for those 
laboratories most familiar with ELISA. To demonstrate this, 
the results of a simple immunoassay using a B. melitensis 
sLPS-coated plate incubated with a biotinylated anti-OPS 
monoclonal antibody and three different conjugates were 
compared. The results (Fig. 3) showed that the streptavidin 
poly-HRP and the streptavidin-coated Europium beads 
(used via TRF) enabled an approximately 30-fold increase 
in analytical sensitivity compared with standard streptavidin 
HRP conjugate (unpublished data).
Improving diagnostic mobility
Nanoparticle TRF can also be exploited in a lateral fl ow 
(LF) immunoassay format where analytical sensitivity 
may be increased between 7- and 300-fold (35). Other 
formulas to increase analytical sensitivity include the use 
of up-converting phosphor technology, which has been 
applied in LF format for the detection of Brucella (66). In 
general, mobile fi eld or ‘pen-side’ assays for brucellosis 
could be of considerable value (1, 9). In many endemic 
areas, uncontrolled animal movement and a veterinary 
infrastructure that is insuffi cient to supply and deliver 
consistently on the outcomes of a centralised testing 
laboratory are major obstacles. These problems might be 
partially bypassed by the application of fi eld tests. To be 
effective in this context the tests must be extremely reliable, 
to give the user confi dence that they can take rapid, 
possibly even immediate, action on the outcome of the test 
result. The quantifi cation of data from such devices as an 
aid to interpretation would be a useful step in this direction. 
Lateral fl ow devices based upon a competitive format, 
developed by using an anti-Brucella OPS monoclonal 
antibody (mAb) conjugated with colloidal gold, have been 
developed in a fashion analogous to that of the competitive 
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Detection of anti-Brucella O-polysaccharide monoclonal 
antibody using three different streptavidin conjugates
The line graph shows the signal response in optical density (OD) and 
relative fl uorescent units (RFU) on the y-axis against the concentration 
of a biotinylated anti-Brucella OPS monoclonal antibody (mAb) added 
to a Brucella smooth lipopolysaccharide-coated indirect enzyme-linked 
immunosorbent assay plate. The signals for three different streptavidin 
conjugates: horseradish peroxidase (HRP), poly-HRP and Europium 
nanoparticles (each used at 0.4 µg/ml) are shown
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line of sLPS antigen, indicates the presence of competing 
serum antibody and a positive response (unpublished data). 
A control line was also printed which consisted of an anti-
monoclonal antibody. Within the context of this review 
the main points to consider are: the ability to print and 
interrogate multiple lines on the device, the ability to read 
the output by eye and by a hand-held quantitative reader, 
and the fact that the quantitative output gave more certainty 
to the interpretation (Fig. 4).
Increasing diagnostic specifi city
Novel platforms, whether laboratory- or fi eld-based, are 
interesting and welcome, but the biological components of 
the assay remain the key to the outcome. To improve the 
specifi city of the serodiagnosis of brucellosis the challenge 
has been to fi nd a reliable alternative antigen to the OPS 
or the sLPS. The current reliance upon the OPS creates 
the confounding problem of false-positive results, caused 
either by infection of the host with Gram-negative bacteria 
in possession of OPS similar in structure to that possessed 
by smooth Brucella (15) or by vaccination with the smooth 
strains B. melitensis Rev.1 or B. abortus S19.
Many potentially diagnostically useful protein antigens have 
been reported, too many to list here, but some examples are 
Lumazine synthase (27), copper/zinc superoxide dismutase 
(Cu/Zn SOD) L7/L12 (4), and malate dehydrogenase (45). 
Perhaps the most frequently cited is BP26 – also known 
as outer membrane protein (OMP)28 (12, 18, 40, 44, 
67). Despite the preponderance of publications extolling 
the virtues of one antigen or another, no antigen has been 
universally acclaimed as a solution. Thus, although the 
search goes on, it seems most unlikely that screening assays 
will be based on anything other than the OPS. However, 
an independent confi rmatory assay built on a non-OPS 
antigen and not expressed by an effective vaccine would be 
extremely useful.
The increased availability of fragmentation mass 
spectrometry protein identifi cation systems, combined 
with genome data and refi nement of two-dimensional gel 
electrophoresis (2DGE) methods, makes the identifi cation 
of proteins derived from immunoselection procedures 
more accessible. As such, new potential diagnostic and 
vaccine candidates for brucellosis continue to be identifi ed 
(4, 14, 39, 62, 84). A downside with this approach is that 
the proteins under investigation are only those expressed 
under the particular laboratory circumstances within which 
Fig. 4
Quantitative output from a competitive lateral fl ow device for the detection of anti-Brucella antibodies in bovine sera
The scatter plot shows the quantitative data from a Brucella smooth lipopolysaccharide (sLPS) competitive enzyme-linked immunosorbent assay (cELISA; 
x-axis) against the data from a homologous competitive lateral fl ow device (cLFD) for bovine sera from B. abortus-infected animals (x and •) and non-
infected animals (  and ). The positive/negative cut-offs for each assay are shown by dashed lines. The differentiation of the data points within each 
infection status shows what the visual only (by ‘Eye’) interpretation of the cLFD result was for each sample. Samples from infected animals interpreted 
by eye as positive are shown as ‘’, those interpreted as negative by eye are shown as ‘•’. Samples from non-infected animals interpreted by eye as 
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the Brucella cells were grown and from which the proteins 
were derived. An alternative approach that, in theory, 
enables the immunoassessment of all proteins within the 
genome is to express these proteins via a recombinant gene 
expression library and then probe the library with immune 
sera (45) to identify the recombinant clones from which the 
sequence of the protein of interest can be determined. A 
third approach is to synthesise recombinant antigens from 
all the open reading frames (ORFs) and probe all of these 
against antisera via microarray (42). Yet there are technical 
challenges to the recombinant approaches, not least of 
which is the uncertainty regarding whether all the proteins 
are in their native confi guration. 
Unlike a repeating polysaccharide, such as the Brucella OPS, 
proteins contain many different epitopes. Some of these may 
be immunodominant and others not. Some may be unique 
to Brucella, and others, even though the protein as a whole is 
unique, may not be. Therefore, investigation of the immune 
response at the peptide rather than the protein level may 
be the way forward (6). In support of this, several papers 
have demonstrated that truncated BP26 antigens may be 
more effective diagnostic antigens (68, 73). A recent study 
(65) has separately evaluated individual and overlapping 
peptides from the BP26 protein using monoclonal 
antibodies and evaluated the most promising peptides as 
diagnostic antigens in iELISA, with some modest success. 
Mapping peptide epitopes from B. burgdorferi has led to the 
discovery of specifi c peptides that enabled differentiation, 
via the antibody response, between active and past disease 
(10). This approach, eliminating non-specifi c antigens 
and operating at the epitope level, is ripe for enhancement 
by systems, such as those described above, that increase 
analytical sensitivity and enable the effi cient combination 
of several antigens.
Whole proteome immuno-screening is a challenge; 
screening all peptide sequences within the proteome 
magnifi es this challenge many fold. Bioinformatics may help 
to reduce the workload by predicting which proteins are 
the most likely to generate a signifi cant immune response. 
A recent study used the complete human serum antibody 
response to the B. melitensis proteome to predict what types 
of protein are likely to be immunogenic candidates (43). 
It may be unsurprising that properties such as membrane 
association and secretion were positively associated with 
antigen recognition by antibodies. Indeed, one-third of 
the proteome contained such enriching features, and 
they accounted for 91% of the antigens recognised by the 
humoral immune system after B. melitensis infection. This 
type of approach was used with some success to identify 
peptides that could aid the diagnosis of bovine tuberculosis. 
By predicting the proteins that are secreted by M. bovis, 
using experimental and theoretical data, the proteome was 
reduced to 119 DIVA candidates. From these, 4,162 20-mer 
(with 12-mer overlap) peptides were evaluated for their 
ability to stimulate the memory T-cell response in infected 
cattle (33). From among these, in turn, a cocktail of nine 
peptides was identifi ed that reacted in 54% of infected 
animals, with no reaction from animals vaccinated with 
bacille Calmette−Guérin (BCG) (34). 
Once candidate proteins have been identifi ed, the peptides 
within may be screened in silico for their potential to elicit an 
immune response. Two programmes for the identifi cation 
of T-cell epitopes were tested against existing data on the 
immune response to 105 peptides derived from a number 
of proteins from M. bovis (32). The selection processes 
identifi ed a panel that contained a higher proportion 
of reactive peptides than the initial set but some good 
sequences were lost. Selection software tools for antibody 
peptide epitopes are widespread, although they are more 
directly targeted towards highlighting good potential 
vaccine candidates and targets for monoclonal antibody 
generation than for the identifi cation of potential diagnostic 
antigens (78). To narrow the scope of in vitro investigation 
further, a peptide BLAST search would identify sequences 
that are insuffi ciently unique to the organism of interest and 
may have poor specifi city. 
It is likely that despite in silico analysis many peptides from 
a full proteomic investigation would still require in vitro 
analysis. High-throughput solutions for peptide microarray 
are becoming ever more available through a number of 
commercial suppliers and it is now commonplace to 
be able to put up to 104 peptides on a single array (55). 
The feasibility of the approach is presented by a study 
into the antibody response against peptides derived from 
61 proteins from M. tuberculosis. This was conducted using 
a high content microarray containing 7,446 individual 
peptides (23) and the results were informative, although it 
should be said that the data generated required powerful 
and considered interpretation. Perhaps more impressive 
than this was the application of the same array to the 
identifi cation of peptides that bound to recombinant major 
histocompatibility complex (MHC) antigens and thus may 
be possible T-cell epitopes (24). 
Developments in the use of the cellular immune response 
as a means to diagnose brucellosis have been comparatively 
few. This is in contrast to the development of interferon-
gamma (IFNg) assays for bovine tuberculosis, for example, 
where specifi c proteins, peptides and ‘negative’ antigens 
have been extensively evaluated as stimulators of the 
T-cell response (76). There is obviously a greater need for 
such development for bovine tuberculosis owing to the 
unavailability of an established serological assay. Although 
the skin test is favoured by some as a means to diagnose 
brucellosis (26), the value of in vitro cytokine assays for 
this purpose seems stymied by the complex and variable 
cytokine response to infection (20).
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Proteins and peptides are not the only source of structural 
specifi city within Brucella. All Brucella OPS antigens 
possess within them unique epitopes, as demonstrated 
by monoclonal antibodies and structural investigations 
(54). It was remarked upon some time ago that the use 
of these specifi c epitopes, some of which have been 
laboratory synthesised (8), as diagnostic antigens may yield 
diagnostics with improved specifi city (80), especially as 
there is evidence of polyclonal antibodies within Brucella-
infected cattle that possess the required specifi city (38). At 
the time of writing there were no data publicly available 
to demonstrate the effi cacy, or otherwise, of this approach. 
More mainstream is the application of rough LPS as a 
diagnostic antigen. Antigens dominated by rough LPS have 
been used successfully for some time in the serodiagnosis 
of infections with B. ovis (64) and B. canis (36). Rough 
LPS has not been used for routine serological detection of 
infection by smooth Brucella species, but there does appear 
to be some potential for its use as part of a testing algorithm 
(48, 61).
Researchers at the Animal Health Veterinary Laboratories 
Agency in the United Kingdom have attempted to bring 
together the potential diagnostic benefi ts from multiplexing 
several different antigens and increasing analytical sensitivity 
via the use of streptavidin poly-HRP. The objective was to 
obtain a serodiagnostic output with improved specifi city 
with the aim of resolving FPSRs. Several Brucella-derived 
antigens were printed within an array within each 
well of a 96-well ELISA plate using a BioDot printer 
(Fig. 5). This included sLPS (from B. abortus S99 and 
Fig. 5
A captured image from a multiplex enzyme-linked 
immunosorbent assay array for the simultaneous detection of 
anti-Brucella antibodies against several antigens
An example image from a serological 96-well chemiluminescent 
multiplex iELISA assay for the detection of bovine antibodies to 
smooth lipopolysaccharide (sLPS) derived from B. abortus (strain S99), 
B. melitensis (strain 16M), Yersinia enterocolitica O9, recombinant 
protein BP26, BrucellergeneTM and rough (r)LPS derived from B. abortus 
(strain RB51). Each spot within the well relates to a specifi c antigen or 
dilution thereof
B. melitensis S19), recombinant protein BP26 (48), native 
whole protein extract BrucellergeneTM and rough LPS derived 
from B. abortus RB51. The results from the antigens within 
the multiplex were similar to those from the equivalent 
separate individual assays for each antigen that were run 
in parallel. However, despite demonstrating a statistically 
signifi cant difference between the mean response to the 
non-OPS- dominated antigens for serum populations from 
Brucella-infected cattle and cattle presenting FPSRs, the 
difference was not suffi cient for a useful diagnostic assay. 
Combining the data from the three non-OPS antigens 
together in an algorithm increased the overall diagnostic 
performance above that of the best individual non-OPS 
assay on its own, but only by a narrow margin (manuscript 
in preparation). This project was admittedly modest in its 
scope and did not achieve its key aim of resolving FPSRs. 
However, several refi nements are possible and there is 
ample opportunity to incorporate additional antigens in 
the future, whether lipid, carbohydrate, protein, peptide or 
combinations thereof. 
That this review has focused on the developments in 
immunodiagnosis rather than methods of detecting specifi c 
DNA or Brucella itself is more a refl ection of the limitations 
of the author rather than developments in direct detection. 
Furthermore, a review covering much of this subject has 
recently been published (81). The author defers to expertise 
elsewhere on the aforementioned topic, but remains of the 
opinion that the interpretation of immune mediators will 
be the linchpin of the diagnosis of animal brucellosis for 
many years to come. There has also been insuffi cient space 
to do justice to the specifi c diagnostic issues surrounding 
vaccination; suffi ce to say that much of the antigen discovery 
research described above has been driven by the desire to 
create an elegant and effective DIVA solution. 
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Les récentes innovations du diagnostic immunologique de la 
brucellose chez les animaux d’élevage et dans la faune sauvage 
J.A. McGiven
Résumé
Bien que des tests diagnostiques relativement effi caces soient disponibles 
depuis plus d’un siècle pour détecter la brucellose, celle-ci demeure une maladie 
grave et bien établie dans certains endroits du monde, voire ré-émergente. Outre 
l’insuffi sance des capacités diagnostiques, de nombreux autres facteurs font 
obstacle à l’éradication complète et durable de la brucellose animale. L’auteur 
plaide en faveur d’une amélioration continue des méthodes diagnostiques, en 
identifi ant les défaillances actuelles et en analysant leurs conséquences sur 
les opérations de contrôle et d’éradication. L’accent est mis sur les innovations 
introduites dans le domaine du diagnostic immunologique, car ces méthodes 
offrent les meilleures perspectives de solution concrète aux problèmes 
rencontrés. Par ailleurs, les méthodes de détection recourant à l’ADN sont déjà 
décrites en détail ailleurs. Le présent article aborde divers aspects tels que le 
coût, les possibilités d’utilisation sur le terrain, la sensibilité et la spécifi cité des 
tests. La mise au point de matériels diagnostiques peu onéreux et de techniques 
à haut débit, la construction d’épreuves multiplexes et la quantifi cation des 
tests rapides de terrain sont examinées en analysant leur pertinence pour la 
lutte contre la maladie. Lors de la détermination des sérologies positives, une 
sensibilité insuffi sante des épreuves due à des réactions croisées avec d’autres 
bactéries ou à la présence de souches vaccinales lisses de Brucella constitue 
également un frein aux efforts d’éradication. Pour résoudre ce problème, l’auteur 
préconise de mettre au point de nouveaux déterminants antigéniques discrets 
et de recourir à des méthodes de sélection in silico et à des outils capables 
d’améliorer la sensibilité analytique afi n de détecter des concentrations 
d’analytes relativement faibles mais potentiellement signifi catives. Dans la 
mesure du possible, l’auteur se réfère à des études dédiées spécifi quement à la 
brucellose. Quelques innovations technologiques intéressantes sont également 
présentées en recourant à des exemples pertinents relatifs à d’autres pathologies. 
Les avancées et innovations récentes ne menacent pas, dans l’immédiat, les 
épreuves sérologiques classiques, mais il existe toutefois un véritable potentiel 
d’amélioration et de complémentarité. 
Mots-clés
Brucella – Brucellose – Détection – Diagnostic immunologique – Épreuves multiplexes – 
Homogène – Sensibilité – Spécifi cité.
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Novedades en el inmunodiagnóstico 
de la brucelosis en el ganado y la fauna salvaje 
J.A. McGiven
Resumen
Aunque desde hace más de 100 años existen pruebas relativamente efi caces 
para diagnosticar la brucelosis, en muchas partes del mundo esta sigue siendo 
una enfermedad grave, pertinaz y a veces también reemergente. Muchos son los 
factores que subyacen a esta situación de insufi ciente diagnóstico, que impide 
la erradicación completa y duradera de la brucelosis animal. El autor aboga por 
una continua mejora de los métodos de diagnóstico, señalando las actuales 
defi ciencias y exponiendo los efectos que tienen sobre el control y la erradicación 
de la enfermedad. El autor se concentra en las novedades en el terreno del 
diagnóstico inmunológico, entendiendo que estos métodos encierran el mayor 
potencial de ofrecer las soluciones prácticas que se necesitan, teniendo en cuenta 
además que últimamente ya se han expuesto en otra parte, con toda claridad, las 
novedades en materia de métodos de detección por el ADN. Se examinan aquí 
cuestiones como el costo, la movilidad, la sensibilidad y la especifi cidad de las 
distintas pruebas. También se describen los avances obtenidos en lo tocante a 
materiales de bajo costo, pruebas de elevado rendimiento, ensayos múltiples o 
cuantifi cación de las pruebas rápidas de terreno, y se expone la relación que 
todo ello guarda con la lucha contra la enfermedad. Otro impedimento para lograr 
erradicar la brucelosis reside en la escasa especifi cidad de las pruebas a la 
hora de resolver una serología positiva, debido a la infección con bacterias que 
presentan reactividad cruzada y a la vacunación con cepas lisas de Brucella. Para 
soslayar este problema el autor preconiza la obtención de nuevos determinantes 
antigénicos discretos, junto con herramientas y métodos de selección in silico que 
permitan alcanzar la sensibilidad analítica requerida para detectar sustancias 
que quizá estén presentes en cantidad escasa, pero aun así signifi cativa. 
Siempre que ha sido posible se han tomado las referencias de estudios referidos 
a la brucelosis. En ciertos casos, sin embargo, se han empleado otros ejemplos 
alternativos para exponer ciertas novedades tecnológicas que merecía la pena 
examinar. El autor concluye que, pese a todas las novedades e innovaciones, 
las pruebas serológicas clásicas no parecen amenazadas de extinción masiva, 
aunque sí hay margen para perfeccionarlas sensiblemente y complementarlas.
Palabras clave
Brucella – Brucelosis – Detección – Ensayo multiplex – Especifi cidad – Homogéneo – 
Inmunodiagnóstico – Sensibilidad.
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